Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis

Table 2

Randomized, double-blind, controlled trials testing the effect of gabapentinoids.

Study	Active drug	Control	Sample size	NP condition	Outcome measure	Pain outcome	Adverse events (>10%)
Baba et al. [11]	Mirogabalin 15/20/30 mg	Placebo	834	DPN	0–10 NRS	Positive	Nasopharyngitis (16.4%), somnolence (14.5%), and dizziness (18%)
Jiang et al. [12]	Pregabalin 300–600 mg	Placebo	128	Radiotherapy-induced NP	0–10 NRS	Positive	Dizziness (18.8%) and somnolence (20.3%)
Kato et al. [13]	Mirogabalin 15/20/30 mg	Placebo	765	PHN	0–10 NRS	Positive	Somnolence (23.9%), nasopharyngitis (12.9), and dizziness (15.5%)
Huffman et al. [14]	Pregabalin CR 82.5–660 mg	Placebo	413	PHN	NPS	Positive	Dizziness (17.1%) and somnolence (11.4%)
Liu et al. [15]	Pregabalin 300 mg	Placebo	220	PHN	0–10 NRS	Positive	Dizziness (24.3%)
Merante et al. [16]	Mirogabalin 15/20/30 mg	Placebo	452	DPN	PGIC, BPI	Positive	Dizziness (15.8%) and somnolence (12.3%)
Raskin et al. [17]	Pregabalin 150–300 mg	Placebo	301	DPN	0–10 NRS	Negative	Dizziness (10.3)
Freeman et al. [18]	Gabapentin 1800 mg	Placebo	721	PHN	0–100 NRS	Positive	Not reported
Holbech et al. [10]	Pregabalin 300 mg	Placebo	69	Painful polyneuropathy	0–10 NRS	Positive	Dizziness (16%), oedema (16%), and weight gain (14%)

NP: neuropathic pain; DPN: diabetic painful neuropathy; PHN: postherpetic neuralgia; NRS: numerical rating scale; NPS: neuropathic pain scale; PGIC: patient global impression of change; BPI: brief pain inventory.